Back to news

Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol

PR Newswire•16/11/2026•08:00 ET
1

Key Highlights

  • ➤Aramchol LNP formulation developed using FDA-approved lipids
  • ➤Formulation targets tumor microenvironment in liver and GI tumors
  • ➤Treatment aims to selectively inhibit fibrosis-driving cells
  • ➤Eocene and Barcode apply tumor-targeting LNP technology to Aramchol

Expert Statements

Allen Baharaff, President and Chief Executive Officer of Eocene

“Liver and other cancers often arise in fibrotic tissue as a result of chronic disease. Fibrosis creates an environment that suppresses immune cells and protects the tumor from the immune system and immunotherapy. Immunotherapy can initially elicit significant therapy responses which diminish for many patients, and we believe the fibrotic barrier is a key contributor. We believe Aramchol's novel LNP treatment could potentially make immunotherapy and other standard of care for liver and GI cancer therapies, work better for more patients for longer time and better results.”

Ronen Eavri, Chief Executive Officer of Barcode-Nanotech

“Building on our earlier work with Galmed to deliver Aramchol to the brain and the heart, we are now applying our proprietary lipid library and in vivo, AI-based screening platform, including our tumor-targeting LNP technology, to the development of an Aramchol LNP formulation directed to the tumor microenvironment of liver and GI cancers. By selectively reaching the cells that drive fibrosis, we hope to help immunotherapy and other standard-of-care treatments work for more patients.”

Eocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol PR Newswire

* A unique proprietary lipid nanoparticles (LNPs) novel formulation of Aramchol has been developed using FDA-approved Lipids * The novel formulation is designed to redirect Aramchol's biodistribution to target tumor microenvironment (TME) in liver and GI tumors and selectively inhibit the activity of cells that drive fibrosis * By selectively targeting TME cells that drive fibrosis, the Aramchol LNP treatment could make immunotherapy and other standard of care liver and GI cancer therapies, work better for more patients with minimal toxicity GIVATAYIM, Israel, Nov. 16, 2026 /PRNewswire/ -- Eocene Ltd. (NASDAQ: EOCN) ("Eocene" or the "Company") report today updates from its wholly owned subsidiary, Galmed Research & Development Ltd. ("Galmed"), ongoing collaborative research with Barcode Nanotech ("Barcode"). Based on Barcode's proprietary tumor targeting delivery LNPs formulation platform, a novel Aramchol LNPs formulation was developed. The new LNP formulation aims to redirect Aramchol's biodistribution to target tumor microenvironment (TME) in liver and GI tumors.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in